Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2006

View Archived Issues

De Novo enters drug discovery collaboration with Genzyme

Potent and selective AEA reuptake inhibitors as antispastics in MS

A.P. Pharma sells royalty rights to Retin-A Micro and Carac

New investment supports GammaCan's phase II study of GCAN-101

BioVeris signs option agreement with TheraCarb for C. albicans vaccine candidate

Merck Frosst presents a new potent, selective orally active cathepsin K inhibitor

Phase I study completed for KB-2115

Department of Defense grant for preclinical study of Tarvacin for prostate cancer

Positive phase III results for SPP-100 in hypertension

Shareholders vote in favor of Crucell's offer for Berna

NanoCarrier to conduct phase I study of Nanoplatin in U.K.

Tolamba shows clinical benefit in reducing symptoms of ragweed allergy

GdSSR: A novel putative approach for glioblastoma multiforme treatment

NovImmune files IND for antibody for autoimmune disease

EDP-420 begins North American phase II trial for CAP

Enrollment nearing completion in phase IIIb mesothelioma study of Onconase

Phase III development of Acapodene recommended to continue

Panzem studied in phase II for recurring GBM

Arteriocyte studies adult derived hemangioblasts to treat chronic ischemia

Procyon Biopharma and Cellpep to merge to form Ambrilia Biopharma

HPV-specific inhibitors from Boehringer Ingelheim as a gateway for future drug design

Novel agents imparted for inflammatory disorders

Taisho patent describes compounds with potential for the treatment for renal disorders, etc.

Recent patents cover novel treatments for psychological disorders

Neuroprotective effects of targeting IKK for stroke

New therapeutics for cancer covered in recent patent literature

SuperGen withdraws Orathecin MAA

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026